Document Type
Article
Publication Date
1-1-2023
Original Citation
Sproule TJ,
Wilpan R,
Wilson J,
Low BE,
Kabata Y,
Ushiki T,
Abe R,
Wiles MV,
Roopenian DC,
Sundberg J.
Dystonin modifiers of junctional epidermolysis bullosa and models of epidermolysis bullosa simplex without dystonia musculorum. PLoS One. 2023;18(10):e0293218.
Keywords
JMG, Animals, Mice, Dystonia, Dystonic Disorders, Dystonin, Epidermolysis Bullosa, Epidermolysis Bullosa Simplex, Epidermolysis Bullosa, Junctional, Skin
JAX Source
PLoS One. 2023;18(10):e0293218.
ISSN
1932-6203
PMID
37883475
DOI
https://doi.org/10.1371/journal.pone.0293218
Grant
DCR received award Roopenian-1 from Debra Austria https://www.debra-austria.org/ and Roopenian-2 from Debra UK https://www.debra. org.uk/. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Abstract
The Lamc2jeb junctional epidermolysis bullosa (EB) mouse model has been used to demonstrate that significant genetic modification of EB symptoms is possible, identifying as modifiers Col17a1 and six other quantitative trait loci, several with strong candidate genes including dystonin (Dst/Bpag1). Here, CRISPR/Cas9 was used to alter exon 23 in mouse skin specific isoform Dst-e (Ensembl GRCm38 transcript name Dst-213, transcript ID ENSMUST00000183302.5, protein size 2639AA) and validate a proposed arginine/glutamine difference at amino acid p1226 in B6 versus 129 mice as a modifier of EB. Frame shift deletions (FSD) in mouse Dst-e exon 23 (Dst-eFSD/FSD) were also identified that cause mice carrying wild-type Lamc2 to develop a phenotype similar to human EB simplex without dystonia musculorum. When combined, Dst-eFSD/FSD modifies Lamc2jeb/jeb (FSD+jeb) induced disease in unexpected ways implicating an altered balance between DST-e (BPAG1e) and a rarely reported rodless DST-eS (BPAG1eS) in epithelium as a possible mechanism. Further, FSD+jeb mice with pinnae removed are found to provide a test bed for studying internal epithelium EB disease and treatment without severe skin disease as a limiting factor while also revealing and accelerating significant nasopharynx symptoms present but not previously noted in Lamc2jeb/jeb mice.
Comments
© 2023 Sproule et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.